Although sotorasib’s pivotal study had about 18% racial and ethnic minorities in the clinical trial, this is somewhat misleading as a total of 15% of clinical study participants were Asian, and in general the KRAS G12C mutation in NSCLC patients is more common in the White and Black patient population than in Asian patients. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.